tiprankstipranks
Blurbs

Needham Sticks to Their Buy Rating for Inogen (INGN)

In a report released today, Michael Matson from Needham maintained a Buy rating on Inogen (INGNResearch Report), with a price target of $47.00. The company’s shares closed last Monday at $27.40.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 10.3% and a 55.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Inogen is a Hold with an average price target of $43.50.

See Insiders’ Hot Stocks on TipRanks >>

Inogen’s market cap is currently $737.9M and has a P/E ratio of 66.21.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inogen, Inc . engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G2 system, and Inogen at Home. The company was founded by Alison Perry, Alison Bauerlein, Brenton Taylor and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

Read More on INGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed